Equibles does not estimate personal net worth.
Get an email with a short summary when Arcturus Therapeutics Holdings Inc. publishes a filing, an earnings call transcript or a press release.
Get ARCT alertsJoseph Payne is recorded as Board Member at Arcturus Therapeutics Holdings Inc. (ARCT) since January 1, 2013 and CEO at Arcturus Therapeutics Holdings Inc. (ARCT). Joseph Payne was last confirmed as Board Member at GRI Bio, Inc. (GRI) in a filing dated April 27, 2022. The proxy statement of Arcturus Therapeutics Holdings Inc. reports total compensation of $1,691,000 for Joseph Payne in fiscal 2025, including a base salary of $750,000. Disclosed compensation is on record for 8 fiscal years. Joseph Payne has spoken on 22 earnings calls and 1 other investor event across 1 company, most recently for Arcturus Therapeutics Holdings Inc. on August 11, 2026. Arcturus Therapeutics Holdings Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Arcturus Therapeutics Holdings Inc. includes Joseph E. Payne (CEO and Board Member), Andy Sassine (CFO and Board Member), Dennis Mulroy (CFO) and 7 others.
“So mRNA, well, Arcturus is an mRNA medicines company. We're based in San Diego, and we're a next generation mRNA company with technologies that are differentiated from the other players in the mRNA field.”
“It's good to be with you again, everybody. The first quarter of 2026 was a period of solid execution for Arcturus as we continue to advance our rare disease pipeline and strengthen our leadership team.”
“It's good to be with you again, everybody. I will begin today with an update on our ARCT-032 and ARCT-810 programs. These are the messenger RNA therapeutic candidates for cystic fibrosis and ornithine transcarbamylase deficiency, respectively.”
“It's good to be with you again, everybody. I will begin today with an update on our ARCT032 program. This is our messenger RNA therapeutic candidate for cystic fibrosis, or CF.”
“It's good to be with you again, everybody. I will begin with our ARCT-032 program. This is our messenger RNA therapeutic candidate for Cystic Fibrosis.”
2013-01-01–present
Start not stated–2022-04-27
Last confirmed by a filing; no departure on record
Biotechnology · Healthcare
CEO, Board Member
2013-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Arcturus Therapeutics Holdings Inc. (ARCT) | CEO | $750,000 | $1,691,000 |
| 2024 | Arcturus Therapeutics Holdings Inc. (ARCT) | CEO | $695,000 | $3,697,000 |
| 2023 | Arcturus Therapeutics Holdings Inc. (ARCT) | CEO | $698,000 | $4,892,500 |
| 2022 | Arcturus Therapeutics Holdings Inc. (ARCT) | CEO | $630,000 | $5,594,000 |
| 2021 | Arcturus Therapeutics Holdings Inc. (ARCT) | CEO | $600,000 | $960,000 |
| 2020 | Arcturus Therapeutics Holdings Inc. (ARCT) | CEO | $500,000 | $12,861,500 |
| 2019 | Arcturus Therapeutics Holdings Inc. (ARCT) | CEO | $450,000 | $1,165,818 |
| 2018 | Arcturus Therapeutics Holdings Inc. (ARCT) | CEO | $425,000 | $2,687,044 |
